Osteosarcoma (OS) is the fifth most common cancer in children. Although cytotoxic chemotherapy and improved surgical approaches have increased the overall long-term survival rate to 70%, patients with metastatic disease have a survival rate lower than 20%. The biology of OS has become the focus of recent attention, and an improved understanding could lead to new pathways of treatment. The role of parathyroid hormone receptor (PTHR1) signaling in OS has never been defined, nor indeed has that of PTH-related protein (PTHrP). Our recent findings suggest that PTHR1 acts to promote tumor invasion and proliferation in OS.

Induction of OS in rats by radiophosphorus injection yielded tumors that were markedly PTH-responsive.[@cit0001] In that study, removing the source of PTH by parathyroidectomy had no influence on any aspect of OS, but that was many years before the existence of PTHrP was appreciated. Subsequent studies in OS cell lines from several species have established PTH responsiveness as a common, if not universal, feature of OS.[@cit0002] PTHR1, a G-protein coupled receptor linked to adenylyl cyclase, is activated by the N-terminal regions of both PTH and PTHrP. PTHrP was discovered as the factor responsible for the humoral hypercalcemia of cancer, and was found to act physiologically as a paracrine/autocrine factor in many tissues, including bone, where it is produced by cells in the osteoblast lineage.[@cit0003] There are 3 main subtypes of OS: osteoblastic, fibroblastic, and chondroblastic. Genetically engineered mouse models of OS have been used to generate the fibroblastic subtype by deletion of *p53* and *pRb* from the osteoblast lineage[@cit0004], and the osteoblastic subtype by shRNA-mediated knockdown of *p53* within the osteoblast lineage.[@cit0005] Primary and metastatic tumors from either subtype express functional PTHR1. OS cultures of both subtypes responded to treatment with either PTH or PTHrP with the expected changes in gene expression[@cit0005] and all expressed PTHrP.[@cit0006]

The functional relevance of PTHR1 to OS biology has not been clearly defined *in vivo*. Consistent with a role for PTHR1 in OS, higher expression of *PTHR1* mRNA was detected in metastatic or relapsed samples of a human OS series than in primary sites, and overexpression of PTHR1 in an OS cell line increased proliferation and invasion.[@cit0007] Knockdown of *PTHR1* in murine fibroblastic OS resulted in reduced tumor cell invasion *in vitro* and changes in gene expression that reflected loss of activation of PTHR1 and cAMP-dependent protein kinase A (PKA).[@cit0006] Notably, *PTHR1* knockdown resulted in greatly reduced proliferation and increased mineralization of the tumor *in vivo*. PTHrP was present as an intracellular protein in OS cells, but its secretion was very low to undetectable. Interestingly, treatment with a neutralizing monoclonal antibody against PTHrP failed to modify OS cell proliferation *in vitro* or to influence tumor size *in vivo*. Although the latter findings, together with evidence for its nuclear localization in these and in other cells,[@cit0003] suggest that PTHrP might be acting in an intracrine manner in OS, in such a situation the action of PTHrP on PTHR1 would be difficult to explain. It seems more likely that an autocrine/paracrine action of PTHrP is responsible and that the antibody is insufficiently effective in this context.

The role of PKA activation in endocrine tumors is well known and the subject of recent interest in OS. In mice with osteocalcin promoter-driven SV40T/t antigen-induced OS, a subset of OS with low expression of the α regulatory subunit of PKA type I (PRKAR1A) was identified.[@cit0008] This PRKAR1A-low OS was highly invasive, leading to the conclusion that *Prkar1a* is an OS tumor suppressor. The functional consequence of reduced PRKAR1A is enhanced PKA activity. Consistent with a role of elevated PKA activity, an OS was identified with amplification of *Prkaca*, which encodes the catalytic component of PKA, and *Prkaca* RNA was shown to be overexpressed in that tumor. It seems that enhanced PKA signaling in OS might be mediated by later events in the PKA/CREB cascade, rather than strictly being ascribed to *Prkar1a* as a tumor suppressor. [**Figure 1**](#f0001){ref-type="fig"} illustrates changes in the PKA pathway induced through these mechanism and through PTHrP/PTHR1. Figure 1.Alterations in the PTHrP→PTHR1→PKA pathway in osteosarcoma. (**A**) In normal osteoblasts, autocrine or paracrine parathyroid hormone-related protein (PTHrP) binds and activates its receptor, PTHR1. Activation of PTHR1 causes the generation of cyclic AMP (cAMP) from ATP through adenylyl cyclase. cAMP induces the dissociation of cAMP-dependent protein kinase (PKA) from its regulatory subunits, including the α regulatory subunit of PKA type I (PRKAR1A). Once activated, PKA is able to move to the nucleus, where it phosphorylates and activates CREB. This leads to the activation of target genes downstream of PTHR1 signaling. (**B**) In osteosarcoma cells, various aberrations in the PTHrP→PTHR1→PKA pathway that result in increased activation of the PKA pathway have been described. 1. Elevated production of PTHrP that can bind PTHR1 and stimulate cAMP formation. 2. Increased surface copy number of PTHR1. 3. Mutations in *PRKAR1A* that lead to increased PKA activity. 4. Amplification of *Prkaca,* which encodes the catalytic component of PKA.

Also of interest is the observation that loss of PRKAR1A increased the production of receptor activator of nuclear factor κB ligand (RANKL) in OS,[@cit0008] whereas upon PTHR1 knockdown the expression of RANKL expression decreased and that of osteoprotegerin (OPG) increased.[@cit0006] Two aspects of RANKL biology are significant in OS. It promotes both osteoclast formation, thereby favoring tumor establishment and proliferation, and the establishment and growth of metastatic cancers in bone. Importantly, however, there are also examples of osteoclastogenesis-independent effects of RANKL: blockade of RANKL/RANK can inhibit metastasis to bone by preventing cell migration, and RANKL can promote breast cancer metastasis to bone by a pro-migratory effect through its receptor, RANK, expressed on the cancer cells.[@cit0009] Furthermore, in OS RANKL stimulated both invasion through matrigel and anchorage-independent growth, and each of these effects was prevented by blockade of the RANKL receptor.[@cit0010]

Taken together, these findings provide a compelling case for a role of the PTHrP→PTHR1→PKA axis in the maintenance of OS. If the driver through this axis is indeed PTHrP, manipulating this upstream target, for example through small-interfering RNA or neutralizing antibodies, could be used to regulate OS behavior.
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